Search results for "interval"

showing 10 items of 1703 documents

Validity of long-term and short-term recall of occupational sitting time in Finnish and Chinese office workers.

2020

Abstract Background As sedentary behavior is a global health issue, there is a need for methods of self-reported sitting assessment. The accuracy and reliability of these methods should also be tested in various populations and different cultural contexts. This study examined the validity of long-term and short-term recall of occupational sitting time in Finnish and Chinese subgroups. Methods Two cohort groups of office-based workers (58.6% female, age range 22–67 years) participated: a Finnish group (FIN, n  = 34) and a Chinese group (CHI, n  = 36). Long-term (past 3-month sitting) and short-term (daily sitting assessed on 5 consecutive days) single-item measures were used to assess self-r…

Occupational sittingAdultMalemedicine.medical_specialtyChinaTime FactorsDaily recallPhysical Therapy Sports Therapy and RehabilitationSittingSitting timeOffice workersValidity03 medical and health scienceslcsh:GV557-1198.995Young Adult0302 clinical medicineAccelerometryMedicineHumansOrthopedics and Sports Medicine030212 general & internal medicinelcsh:Sports medicineWorkplaceFinlandAgedlcsh:SportsSitting PositionRecallbusiness.industryQuestionnaireReproducibility of Results030229 sport sciencesMiddle AgedSitting timeConfidence intervalTerm (time)Regular paperCohortMental RecallPhysical therapyFemaleSelf ReportSedentary BehaviorOffice workersbusinesslcsh:RC1200-1245Self-reportJournal of sport and health science
researchProduct

The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of …

2008

The aim of this study was to provide further quantitative data on the risk of second nonmelanoma cancers in patients with cutaneous malignant melanoma (CMM). A cohort of 14 560 population-based patients from the Italian Network of Cancer Registries incident during 1985-2002 were included and followed up for further incident cases and vital status. Standardized incidence ratios (SIR) were used to compare the number of observed second cancers with expected cancers. In a total of 69 581 person-years, 1020 second cancers were registered, of which 804.6 were expected (SIR=1.27; 95% confidence interval 1.19-1.35). The risk was similar for males and females, (SIR=1.27 and 1.26, respectively). The …

OncologyAdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsSettore MED/06 - Oncologia MedicaPopulationDermatologyCohort StudiesRisk FactorsInternal medicineEpidemiology of cancerMedicineHumansRegistriesSurvivorseducationMelanomaAgedAged 80 and overeducation.field_of_studybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseasehumanitiesConfidence intervalcutaneous melanomacancerOncologyItalyCohortCutaneous melanomaFemalesecond cancer - survivors - malignant melanomabusinessCohort studyFollow-Up StudiesMelanoma research
researchProduct

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer

2021

Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in cancer patients as a component of extracellular vesicles, plays a key role in the incidence of cancer‐associated thromboembolism in patients with pancreatic cancer. However, no prospective studies have been published on the relationship between tissue factor and cancer‐associated thromboembolism or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address this in a Japanese cohort of 197 patients and 41 healthy volunteers. Plasma tissue factor levels were mea…

OncologyAdultMaleRiskCancer Researchmedicine.medical_specialtyEnzyme-Linked Immunosorbent AssayThromboplastinCohort StudiesTissue factorExtracellular VesiclesJapanClinical ResearchPredictive Value of TestsPancreatic cancerInternal medicineThromboembolismmedicineConfidence IntervalsHumansRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryCancerpancreatic neoplasmGeneral MedicineExtracellular vesicleOriginal ArticlesVenous ThromboembolismMiddle Agedmedicine.diseasetissue factorPancreatic NeoplasmsOncologyrisk factorRelative riskCase-Control StudiesCohortMultivariate AnalysisOriginal ArticleFemaleextracellular vesiclebusinessCancer Science
researchProduct

Frequency of a positive family history of colorectal cancer in general practice: a cross-sectional study.

2016

BACKGROUND Evidence on the frequency of a positive family history of colorectal cancer (CRC) among individuals aged <55 years is lacking. General practice setting might be well suited for the identification of individuals in this above-average risk group. OBJECTIVE To determine the frequency of a reported positive family history of CRC among patients aged 40 to 54 years in a general practice setting. METHODS We conducted a cross-sectional study in 21 general practices in Germany. Patients aged 40 to 54 years were identified by means of the practice software and interviewed by health care assistants using a standardized four-item questionnaire. Outcome was occurrence of a positive family his…

OncologyAdultMalemedicine.medical_specialtyAdenomaCross-sectional studyColorectal cancerGeneral PracticeColonic PolypsUterine Cervical NeoplasmsNuclear Family03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGermanymedicinePrevalenceHumans030212 general & internal medicineFirst-degree relativesFamily historyMedical History TakingOvarian NeoplasmsUrethral Neoplasmsbusiness.industryCancerMiddle Agedmedicine.diseasedigestive system diseasesConfidence intervalKidney NeoplasmsPedigreeCross-Sectional StudiesGeneral practice030211 gastroenterology & hepatologyFemaleFamily PracticebusinessColorectal NeoplasmsFamily practice
researchProduct

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

2009

Abstract Background In resectable rectal cancer trials, pathological parameters are early preoperative treatment efficacy measures. Their validation as surrogate end points for long-term clinical outcomes would allow to reduce trial duration. The aim was to evaluate potential surrogates for overall survival (OS) and local control (LC) in preoperative T3/T4 rectal cancer trials. Candidate variables included ypT and ypN stages, T downstaging, tumor regression grade (TRG), and circumferential resection margin (CRM) status. Patients and methods In the Federation Francophone de Cancerologie Digestive (FFCD) 9203 trial, 742 eligible patients were randomly assigned to receive preoperative radiothe…

OncologyAdultMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentAdenocarcinomaPreoperative careInternal medicinemedicineHumansNeoadjuvant therapyAgedRandomized Controlled Trials as TopicTumor Regression GradeAged 80 and overbusiness.industrySurrogate endpointRectal NeoplasmsHematologyMiddle Agedmedicine.diseaseChemotherapy regimenCombined Modality TherapyConfidence intervalNeoadjuvant TherapySurgeryClinical trialSurvival RateTreatment OutcomeOncologyFemaleNeoplasm Recurrence LocalbusinessBiomarkersAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Permanent seed brachytherapy for clinically localized prostate cancer: long-term outcomes in a 700 patient cohort.

2015

Abstract Purpose Few large European studies have evaluated long-term outcomes for permanent prostate brachytherapy (PPB) as monotherapy for clinically localized prostate cancer. The objective of the present study was to evaluate long-term survival in this patient profile. Methods and Materials Retrospective study of 700 patients who underwent transperineal ultrasound-guided iodine-125 PPB (145 Gy) between January 2000 and July 2012. Median age was 64.8 years (range, 35–79). Most patients (638 of 700; 91%) had low-risk disease (D'Amico criteria). Eighty-five patients (12%) received hormonal treatment. Overall survival, cause-specific survival, and biochemical relapse–free survival were calcu…

OncologyAdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBrachytherapyBrachytherapyUrologyPermanent prostate brachytherapyKaplan-Meier EstimateCohort StudiesIodine RadioisotopesProstate cancerInternal medicineOverall survivalmedicineLong term outcomesHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesAged 80 and overbusiness.industryProstatic NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseConfidence intervalTreatment OutcomeOncologyCohortbusinessFollow-Up StudiesBrachytherapy
researchProduct

Apolipoprotein E genotype does not influence the progression of multiple sclerosis

2003

OBJECTIVE: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS. METHODS: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined. RESULTS: No association was observed between the APOE epsilon4 allele and clinical characteristics of our study population. We also investiga…

OncologyApolipoprotein EAdultMalemedicine.medical_specialtyMultiple SclerosisGenotypeAdolescentOdds Ratio; Polymorphism Genetic; Chi-Square Distribution; Humans; Disease Progression; Apolipoproteins E; Genotype; Multiple Sclerosis; Adult; Confidence Intervals; Adolescent; Statistics Nonparametric; Female; MalePopulationAPOE polymorphismBiologyStatistics NonparametricApolipoproteins EGeneticPolymorphism (computer science)Internal medicineGenotypeMultiple SclerosimedicineOdds RatioConfidence IntervalsHumansNonparametricPolymorphismeducationGenotypingAPOE promotereducation.field_of_studyExpanded Disability Status ScalePolymorphism GeneticChi-Square DistributionMS progressionStatisticsOdds ratioNeurologyImmunologyDisease ProgressionPopulation studylipids (amino acids peptides and proteins)FemaleSettore MED/26 - NeurologiaNeurology (clinical)Confidence IntervalHuman
researchProduct

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…

2021

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…

OncologyCPS combined positive scoreTC tumor cellsICI immune checkpoint inhibitorTriple Negative Breast NeoplasmsB7-H1 AntigenMedicineHER2 human epidermal growth factor receptor 2Triple-negative breast cancerRC254-282ICC intraclass correlation coefficientbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMSI microsatellite instabilityImmunohistochemistrypCR pathological complete responsePFS progression-free survivalImmunohistochemistryOriginal ArticleIC-ScoreIC immune cellsIHC immunohistochemistryProgrammed deathPD-L1medicine.medical_specialtyConcordanceTNBC triple-negative breast cancerOS overall survivalBreast cancerTriple-negative breast cancerPD-L1Internal medicineTPS tumor proportion scoreBiomarkers TumorHumansProgrammed death-ligand 1Reproducibilitybusiness.industryReproducibility of Resultsmedicine.diseaseITT intention to treatCI confidence intervalPD-L1 programmed death-ligand 1biology.proteinSurgeryCPSbusinessKappaTMB tumor mutational burdenBreast
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index &gt;3% or G3 or Ki67 &gt;20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

2013

The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval […

OncologyCancer Researchmedicine.medical_specialtyBioinformaticsBrief CommunicationDisease-Free Survivallaw.inventionRandomized controlled triallawPredictive Value of TestsStomach NeoplasmsInternal medicinemedicineOdds RatioHumansProgression-free survivalRandomized Controlled Trials as Topicddc:616Surrogate endpointbusiness.industryOdds ratioChemotherapy regimenConfidence intervalTreatment OutcomeOncologyPredictive value of testsMeta-analysisNeoplasm Recurrence LocalbusinessBiomarkersJournal of the National Cancer Institute
researchProduct